Previous 10 | Next 10 |
Avenue Therapeutics (ATXI) -16% after FDA continues to review NDA for IV Tramadol.Lucira Health (LHDX) -12%.OrganiGram (OGI) -12% on FQ2 results.Zomedica (ZOM) -11%.Brooklyn ImmunoTherapeutics (BTX) -10%.Fortress Biotech (FBIO) -9%.Pintec Technology (PT) -8%.Digital Ally (...
NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the U.S. Food and Drug Administration (“FDA ...
Fortress Biotech (FBIO) is trading ~6.0% lower in the post-market hours on the announcement of 600K common stock offering by selling shareholders.Per the prospectus, the investors from time to time will sell 600K shares of the company’s common stock at a par value of $0....
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...
Fortress Biotech Inc. (NASDAQ:FBIO) traded today at a new 52-week high of $5.78. This new high was reached on above average trading volume as 1.8 million shares traded hands, while the average 30-day volume is approximately 1.3 million shares. Fortress Biotech Inc. (NASDAQ:FBIO) is curre...
Shares of Fortress Biotech (FBIO) are 3% higher in premarket trading ahead of an April 12 PDUFA date for IV tramadol for post-surgery acute pain.Fortress is partnered with Avenue Theraupeutics (ATXI), on the program.In October 2020, the FDA issued a complete response letter for the ...
Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...
Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) ...
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectiv...
Top Penny Stocks For Your List Right Now Penny stocks are some of the highest risk investments you can make. But their innate ability to record explosive gains is undeniable. What are penny stocks ? All we’re talking about here are stocks under $5. According to the Securities...
News, Short Squeeze, Breakout and More Instantly...
Fortress Biotech Inc. Company Name:
FBIO Stock Symbol:
NASDAQ Market:
Fortress Biotech Inc. Website:
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...